Merck Pre-Tax Profit Margin 2006-2018 | MRK

Current and historical pre-tax profit margin for Merck (MRK) from 2006 to 2018. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Merck pre-tax profit margin for the three months ending June 30, 2018 was .
Merck Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2018-06-30 $41.26B $5.51B 13.35%
2018-03-31 $40.73B $5.86B 14.40%
2017-12-31 $40.12B $6.52B 16.25%
2017-09-30 $39.80B $3.29B 8.26%
2017-06-30 $40.02B $5.97B 14.93%
2017-03-31 $39.93B $5.04B 12.62%
2016-12-31 $39.81B $4.66B 11.70%
2016-09-30 $39.91B $6.83B 17.12%
2016-06-30 $39.44B $6.34B 16.08%
2016-03-31 $39.39B $5.64B 14.33%
2015-12-31 $39.50B $5.40B 13.67%
2015-09-30 $39.77B $16.40B 41.23%
2015-06-30 $40.25B $15.49B 38.48%
2015-03-31 $41.40B $16.57B 40.03%
2014-12-31 $42.24B $17.28B 40.92%
2014-09-30 $43.08B $6.70B 15.55%
2014-06-30 $43.55B $6.73B 15.46%
2014-03-31 $43.63B $6.09B 13.95%
2013-12-31 $44.03B $5.55B 12.59%
2013-09-30 $44.45B $5.65B 12.72%
2013-06-30 $44.91B $6.35B 14.13%
2013-03-31 $46.21B $7.78B 16.84%
2012-12-31 $47.27B $8.74B 18.49%
2012-09-30 $47.82B $8.99B 18.79%
2012-06-30 $48.36B $9.12B 18.86%
2012-03-31 $48.20B $8.11B 16.83%
2011-12-31 $48.05B $7.33B 15.26%
2011-09-30 $47.85B $5.05B 10.56%
2011-06-30 $46.95B $3.20B 6.81%
2011-03-31 $46.15B $2.77B 5.99%
2010-12-31 $45.99B $1.65B 3.59%
2010-09-30 $43.99B $8.82B 20.05%
2010-06-30 $38.91B $13.40B 34.43%
2010-03-31 $33.47B $14.12B 42.20%
2009-12-31 $27.43B $15.29B 55.75%
2009-09-30 $23.37B $10.78B 46.15%
2009-06-30 $23.26B $7.15B 30.73%
2009-03-31 $23.41B $7.27B 31.06%
2008-12-31 $23.85B $9.93B 41.64%
2008-09-30 $24.06B $4.92B 20.43%
2008-06-30 $24.19B $5.54B 22.89%
2008-03-31 $24.25B $5.68B 23.43%
2007-12-31 $24.20B $3.49B 14.43%
2007-09-30 $24.00B $7.46B 31.10%
2007-06-30 $23.33B $6.63B 28.41%
2007-03-31 $23.00B $6.51B 28.29%
2006-12-31 $22.64B $6.22B 27.48%
2006-09-30 $22.36B $6.83B 30.54%
2006-06-30 $22.36B $7.60B 33.97%
2006-03-31 $22.06B $7.41B 33.60%
2005-12-31 $22.01B $7.36B 33.45%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $195.663B $40.122B
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $372.065B 17.44
Pfizer (PFE) United States $264.129B 15.46
Novartis AG (NVS) Switzerland $201.850B 17.25
AbbVie (ABBV) United States $127.608B 12.47
Eli Lilly (LLY) United States $120.319B 22.27
Sanofi (SNY) France $111.710B 14.14
Novo Nordisk (NVO) Denmark $105.365B 16.84
GlaxoSmithKline (GSK) United Kingdom $100.437B 13.41
AstraZeneca (AZN) United Kingdom $100.024B 11.00
Bristol-Myers Squibb (BMY) United States $83.165B 15.05